UI Hospitals and Clinics

Clinical Trial Details

Short Title
Official Title
Evaluate the Safety of Treatment for Patients with Crohn's Disease

 A Phase 11 Study to Evaluate the Efficacy and Safety of 12 weeks Treatment With Oral CNDO 210 Trichuris Suis Ova Suspension(TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients with Moderatley to Severly Active Crohn's Disease(TRUST 1)

The Objective of this Phase II study  is to evaluate the efficacy and safety of 12 weeks of treatment with oral CNDO 201 Trichuris suis ova suspension (TSO) as compared to placebo, followed by a 12 week open-label treatment period in patients with moderately to severely active Crohn’s disease.

Start Date
July 1, 2012
End Date
August 1, 2013
Gender Preference
Age Group
18 - 65 years
Principal Investigator
Steven Polyak, MD
Contact Info

Dr. Steven Polyak 319-353-8574

steven-polyak @uiowa.edu

Crohn ; Phase 11+Inflammatory bowel disease ; undefined ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.